Eliana Lacerda

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Eliana Mattos Lacerda MD, PhD, MSc, is a Clinical Assistant Professor and part of the CureME team at the London School of Hygiene and Tropical Medicine, London, UK. She oversees the UK ME/CFS biobank, from recruitment of participants through to release of samples.[1]

She has a medical background, with training in public health and occupational health.[1]

EUROMENE[edit | edit source]

Dr. Lacerda is the Vice Chair of EUROMENE, a European Union not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, and was a founder member of the network.[2]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Member of the Baseline/Covariate Working Group and Neurologic/Cognitive/CNS Imaging Working group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[3]

Notable studies[edit | edit source]

  • 2010, Exploring the feasibility of establishing a disease-specific post-mortem tissue bank in the UK: a case study in ME/CFS[4] - (Abstract)
  • 2011, A Disease Register for ME/CFS: Report of a Pilot Study[5] - (Full Text)
  • 2011, Social support needs for equity in health and social care: a thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis[6] - (Full Text)
  • 2011, Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care[7] - (Full Text)
  • 2011, The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers[8] - (Full Text)
  • 2014, Considerations in establishing a post-mortem brain and tissue bank for the study of myalgic encephalomyelitis/chronic fatigue syndrome: A proposed protocol[9] - (Full Text)
  • 2017, How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies?[10] - (Full Text)
  • 2017, The UK ME/CFS Biobank for biomedical research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis[11] - (Full text)
  • 2017, The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE[12] - (Full Text)
  • 2017, Editorial - Using a participatory approach to develop and implement the UK ME/CFS Biobank[13]
  • 2018, Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls[14] - (Full Text)
  • 2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review[15] - (Full text)
  • 2018, The UK ME/CFS Biobank: A Disease-Specific Biobank for Advancing Clinical Research Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[16] - (Full text)
  • 2019, Hope, disappointment and perseverance: Reflections of people with Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis participating in biomedical research. A qualitative focus group study.[17]
  • 2019, Evidence of Clinical Pathology Abnormalities in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) from an Analytic Cross-Sectional Study[18] - (Abstract)
  • 2019, Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[19] - (Full text)
  • 2019, HERV-K and HERV-W transcriptional activity in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome[20] - (Full text)
  • 2019, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a hyper-regulated immune system driven by an interplay between regulatory T cells and chronic human herpesvirus infections[21] - (Abstract)
  • 2019, A logistic regression analysis of risk factors in ME/CFS pathogenesis[22] - (Full text)
  • 2019, How Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) Progresses: A Framework for Research and the Prevention, Treatment, and Rehabilitation in ME/CFS[23] - (Full text)
  • 2020, Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology [24] - (Full text)
  • 2021, The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies[25] - (Full text)

Talks and interviews[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 "Eliana Lacerda". LSHTM. Retrieved April 25, 2019.
  2. ↑ "Action CA15111". COST. Retrieved April 25, 2019.
  3. ↑ "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
  4. ↑ Lacerda, E.M.; Nacul, L.; Pheby, D.; Shepherd, C.; Spencer, P. (November 1, 2010). "Exploring the feasibility of establishing a disease-specific post-mortem tissue bank in the UK: a case study in ME/CFS". Journal of Clinical Pathology. 63 (11): 1032–1034. doi:10.1136/jcp.2010.082032. ISSN 0021-9746.
  5. ↑ Pheby, Derek; Lacerda, Eliana; Nacul, Luis; Drachler, Maria de Lourdes; Campion, Peter; Howe, Amanda; Poland, Fiona; Curran, Monica; Featherstone, Valerie (December 2011). "A Disease Register for ME/CFS: Report of a Pilot Study". BMC Research Notes. 4 (1). doi:10.1186/1756-0500-4-139. ISSN 1756-0500. PMC 3118997. PMID 21554673.
  6. ↑ de Carvalho Leite, JC; de L Drachler, M; Killett, A; Kale, S; Nacul, L; McArthur, M; Hong, CS; O'Driscoll, L; Pheby, D; Campion, P; Lacerda, E; Poland, F (2011), "Social support needs for equity in health and social care: a thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis", International Journal for Equity in Health, 2 (10): 46, doi:10.1186/1475-9276-10-46
  7. ↑ Nacul, Luis C; Lacerda, Eliana M; Pheby, Derek; Campion, Peter; Molokhia, Mariam; Fayyaz, Shagufta; Leite, Jose CDC; Poland, Fiona; Howe, Amanda (December 2011). "Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care". BMC Medicine. 9 (1). doi:10.1186/1741-7015-9-91. ISSN 1741-7015. PMC 3170215. PMID 21794183.
  8. ↑ Nacul, LC; Lacerda, EM; Campion, P; Pheby, D; Drachler, M de L; Leite, JC; Poland, F; Howe, A; Fayyaz, S; Molokhia, M (2011), "The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers", BMC Public Health, 11 (402), doi:10.1186/1471-2458-11-402
  9. ↑ Nacul, L; O'Donovan, DG; Lacerda, EM; Gveric, D; Goldring, K; Hall, A; Bowman, E; Pheby, D (2014), "Considerations in establishing a post-mortem brain and tissue bank for the study of myalgic encephalomyelitis/chronic fatigue syndrome: A proposed protocol", BMC Research Notes, 18 (10): 370, doi:10.1186/1756-0500-7-370
  10. ↑ Nacul, Luis; Lacerda, Eliana M.; Kingdon, Caroline C.; Curran, Hayley; Bowman, Erinna W. (March 1, 2017). "How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies?". Journal of Health Psychology: 1359105317695803. doi:10.1177/1359105317695803. ISSN 1461-7277. PMC 5581258. PMID 28810428.
  11. ↑ Lacerda, Eliana M; Bowman, Erinna W; Cliff, Jacqueline M; Kingdon, Caroline C; King, Elizabeth C; Lee, Ji-Sook; Clark, Taane G; Dockrell, Hazel M; Riley, Eleanor M; Curran, Hayley; Nacul, Luis (February 20, 2017). "The UK ME/CFS Biobank for biomedical research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis". Open Journal of Bioresources. 4. doi:10.5334/ojb.28. ISSN 2056-5542. PMC 5482226. PMID 28649428.
  12. ↑ Scheibenbogen, Carmen; Freitag, Helma; Blanco, Julià; Capelli, Enrica; Lacerda, Eliana; Authier, Jerome; Meeus, Mira; Castro Marrero, Jesus; Nora-Krukle, Zaiga; Oltra, Elisa; Strand, Elin Bolle; Shikova, Evelina; Sekulic, Slobodan; Murovska, Modra (July 26, 2017). "The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE". Journal of Translational Medicine. 15 (1). doi:10.1186/s12967-017-1263-z. ISSN 1479-5876. PMC 5530475. PMID 28747192.
  13. ↑ Lacerda, Eliana M.; Kingdon, Caroline C.; Bowman, Erinna W.; Nacul, Luis (2017). "Using a participatory approach to develop and implement the UK ME/CFS Biobank". Fatigue: Biomedicine, Health & Behavior. doi:10.1080/21641846.2018.1396021.
  14. ↑ Kingdon, Caroline C.; Bowman, Erinna W.; Curran, Hayley; Nacul, Luis; Lacerda, Eliana M. (December 1, 2018). "Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls". PharmacoEconomics - Open. 2 (4): 381–392. doi:10.1007/s41669-018-0071-6. ISSN 2509-4254. PMID 29536371.
  15. ↑ Estévez-López, Fernando; Castro-Marrero, Jesus; Wang, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Nacul, Luis; Sepúlveda, Nuno; Strand, Elin B.; Pheby, Derek; Alegre, José; Scheibenbogen, Carmen; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Lacerda, Eliana; Murovska, Modra (September 1, 2018). "Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review". BMJ Open. 8 (9): e020817. doi:10.1136/bmjopen-2017-020817. ISSN 2044-6055. PMID 30181183.
  16. ↑ Lacerda, Eliana; Mudie, Kathleen; Butterworth, Jack D.; Kingdon, Caroline C.; O'Boyle, Shennae; Nacul, Luis (December 4, 2018). "The UK ME/CFS Biobank: A Disease-Specific Biobank for Advancing Clinical Research Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Frontiers in Neurology. 9. doi:10.3389/fneur.2018.01026. ISSN 1664-2295. PMID 30564186.
  17. ↑ Lacerda, Eliana M.; McDermott, Clare; Kingdon, Caroline C.; Butterworth, Jack; Cliff, Jacqueline M.; Nacul, Luis (January 10, 2019). "Hope, disappointment and perseverance: Reflections of people with Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis participating in biomedical research. A qualitative focus group study". Health Expectations: An International Journal of Public Participation in Health Care and Health Policy. doi:10.1111/hex.12857. ISSN 1369-7625. PMID 30632248.
  18. ↑ Nacul, Luis; de Barros, Barbara; Kingdon, Caroline C.; Cliff, Jacqueline M.; Clark, Taane G.; Mudie, Kathleen; Dockrell, Hazel M.; Lacerda, Eliana M. (April 10, 2019). "Evidence of Clinical Pathology Abnormalities in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) from an Analytic Cross-Sectional Study". Diagnostics. 9 (2): 41. doi:10.3390/diagnostics9020041. ISSN 2075-4418.
  19. ↑ Cliff, Jacqueline M.; King, Elizabeth C.; Lee, Ji-Sook; Sepúlveda, Nuno; Wolf, Asia-Sophia; Kingdon, Caroline; Bowman, Erinna; Dockrell, Hazel M.; Nacul, Luis; Lacerda, Eliana; Riley, Eleanor (April 16, 2019). "Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Immunology. 10. doi:10.3389/fimmu.2019.00796. ISSN 1664-3224.
  20. ↑ Rodrigues, Lucas S; Nali, Luiz H da Silva; Leal, Cibele O D; Sabino, Ester C; Lacerda, Eliana M; Kingdon, Caroline C; Nacul, Luis; Romano, Camila M (July 5, 2019). "HERV-K and HERV-W transcriptional activity in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome". bioRxiv. doi:10.1101/693465.
  21. ↑ Sepúlveda, Nuno; Carneiro, Jorge; Eliana M. Lacerda, Eliana M.; Nacul, Luis C. (October 2019). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a hyper-regulated immune system driven by an interplay between regulatory T cells and chronic human herpesvirus infections". Frontiers in Immunology. doi:10.3389/fimmu.2019.02684.
  22. ↑ Lacerda, Eliana M.; Geraghty, Keith; Kingdon, Caroline C.; Palla, Luigi; Nacul, Luis (December 2019). "A logistic regression analysis of risk factors in ME/CFS pathogenesis". BMC Neurology. 19 (1): 275. doi:10.1186/s12883-019-1468-2. ISSN 1471-2377.
  23. ↑ Nacul, Luis; O'Boyle, Shennae; Nacul, Flavio E.; Mudie, Kathleen; Kingdon, Caroline C.; Cliff, Jacqueline M.; Clark, Taane G.; Dockrell, Hazel M.; Lacerda, Eliana M. (September 17, 2019). "How Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) Progresses: A Framework for Research and the Prevention, Treatment, and Rehabilitation in ME/CFS". Preprints. doi:10.20944/preprints201909.0188.v1.
  24. ↑ Estévez-López, Fernando; Mudie, Kathleen; Wang-Steverding, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Castro-Marrero, Jesús; Nacul, Luis; Alegre, Jose; Zalewski, Paweł; Słomko, Joanna; Bolle Strand, Elin; Pheby, Derek; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Scheibenbogen, Carmen; Sepúlveda, Nuno; Murovska, Modra; Lacerda, Eliana (May 2020). "Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology". Journal of Clinical Medicine. 9 (5): 1557. doi:10.3390/jcm9051557.
  25. ↑ Malato, João; Sotzny, Franziska; Bauer, Sandra; Freitag, Helma; Fonseca, André; Grabowska, Anna D; Graça, Luís; Cordeiro, Clara; Nacul, Luís; Lacerda, Eliana M; Castro-Marrero, Jesus; Scheibenbogen, Carmen; Westermeier, Francisco; Sepúlveda, Nuno (March 24, 2021). "The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies". medRxiv. doi:10.1101/2021.03.23.21254175. PMID 33791744.
Retrieved from "https://me-pedia.org/w/index.php?title=Eliana_Lacerda&oldid=241630"